Biomolecule Contributors to Long COVID Syndrome
A special issue of Biomolecules (ISSN 2218-273X). This special issue belongs to the section "Molecular Medicine".
Deadline for manuscript submissions: 31 December 2024 | Viewed by 5910
Special Issue Editor
Interests: long COVID-19; post-COVID-19; multiorgan disease; cardiac regeneration; cell-based and cell-free therapies; translational animal models of cardiac diseases; ischemic heart diseases
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Long COVID-19 syndrome is a new multiorgan manifestation of SARS-CoV-2 infection, with a prolonged post-viral phase lasting over months or even years in many patients. Depending on the SARS-CoV-2 variants, the prevalence of long COVID-19 syndrome ranges from 3% (newest omicron variant) to 37% (early alpha and beta variants), resulting in an unexpected huge socioeconomic and health burden worldwide. According to disease treatment priority to prevent COVID-19-related death, enormous effort is ongoing to elaborate circulating biomarkers predictive of acute COVID-19 disease severity and outcome and to search for effective treatment options. The mortality rates of long COVID-19 disease are low, even though morbidity rates are high; as such, long COVID-19 syndrome has attracted much less interest in the scientific medical community. However, as the number of patients with long-lasting post-viral syndromes (such as chronic fatigue syndrome, disability, diverse neurological and neuropsychiatric syndrome, leading to inability to work and to carry out daily activities) exponentially increases, research on long COVID-19 syndrome has also come to the front. Several circulating biomarkers or clinical symptoms documented during acute illness have been related to developing long COVID-19 or post-COVID-19 syndrome. However, as over 90% of SARS-CoV-2-infected patients had no medical investigations during the acute phase, predicting the occurrence of long COVID-19 is difficult, if not impossible. Currently, no diagnostic biomolecules or circulating mediators have been identified to be present in patients with long COVID-19 syndrome, and none have been found to be predictive of severity, type, or longevity of long COVID-19 disease.
In this Special Issue of Biomolecules called “Biomolecule Contributors to Long COVID-19 Syndrome”, we invite original research articles or reviews reporting significant diagnostic or prognostic biomolecules, which are related to this new multiorgan disease and in association with the patient clinical presentation.
Prof. Dr. Mariann Gyöngyösi
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- long COVID-19
- post-COVID-19
- post-viral
- SARS-CoV-2
- chronic fatigue syndrome
- multiorgan disease
